Castle Biosciences, Inc. - Common stock · Transaction Mar 15, 2022 · Filed Apr 17, 2022 · $1,001 to $15,000
XNAS · CSTL
+0.14% · +$0.0500 · Vol 39.3K
Live · updated 11:52:02 ET
Castle Biosciences, Inc. Common Stock
SERVICES-MEDICAL LABORATORIES
$35.30
Follow $CSTL
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $CSTL by emailVeridion Score
BETAMEDIUM CONF · 5 of 6 factors measuredThu Oct 1 · last completed session · daily score · 18h old · CSTL
MethodologySentiment absence reason unknown
CSTL
Castle Biosciences, Inc. Common Stock
Thu Oct 1 · last completed session · daily score · 18h old
Upper range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
85/ 100
Veridion Score
Upper range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Thu Oct 1 · last completed session · daily score · 18h old
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is CSTL moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Castle Biosciences, Inc. Common Stock
SERVICES-MEDICAL LABORATORIESListed since
2019
Employees
1K
Country
US
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$35.56
Day high
$35.92
Day low
$35.21
Previous close
$35.26
52W high
$43.04
-17.97% from high
52W low
$18.15
69% of range
Market cap
$1.1B
EPS
$-0.4300
Beta
0.74
Shares out
30.5M
Volume
39.3K
0.11× rel vol
Avg volume
363.3K
VWAP
$35.47
Price history computed in-house
1W
-1.41%
1M
+5.64%
3M
+46.43%
1Y
+58.82%
YTD
-9.24%
SMA 50 $32.12 · above
SMA 200 $29.10 · above
52W position 69%
CSTL overview
Related filings and maps
Public disclosures
Congress activity in CSTL
Official filing ↗
Castle biosciences, Inc. - Common stock · Transaction Dec 23, 2020 · Filed Jan 11, 2021 · $1,001 to $15,000
Castle biosciences, Inc. - Common stock · Transaction Dec 21, 2020 · Filed Jan 7, 2021 · $1,001 to $15,000
Federal contracts
CSTL contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CSTL in this window.
Lobbying spend
CSTL lobbying filings, year to date.
Registered lobbying filings matched to Castle Biosciences, Inc. Common Stock.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CSTL in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for CSTL.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.